Pharmafile Logo

Merdad Parsey

- PMLiVE

Gilead $1bn antibody deal with MacroGenics

Joins Boehringer and Servier in use of US biotech’s DART technology

- PMLiVE

Gilead posts strong data for all-oral hepatitis C treatment

Achieves sustained virologic response in 78 per cent of participants

- PMLiVE

Gilead advances HIV drug into phase III

The treatment is a chemical variant of Gilead's successful HIV drug Viread

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links